Physician profile
Timothy Mcclain
NPI 1730185364
$5,169.32
in general payments reported to CMS, 2019-2025
38 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $537 · 2021: $856 · 2022: $1,162 · 2023: $890 · 2024: $1,055 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,136.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $783.81 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $762.36 | 2019-2025 | Farxiga, Airsupra, Xigduo |
| Lilly USA, LLC | $455.65 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $450.46 | 2021-2024 | |
| Glaxosmithkline, LLC. | $279.52 | 2019-2025 | Shingrix, Arexvy |
| Abbott Laboratories | $258.86 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Amarin Pharma, INC. | $254.58 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.28 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $198.22 | 2019-2024 | Gardasil 9, Vaxneuvance, Capvaxive |
| Pfizer INC. | $184.32 | 2019-2024 | |
| Exact Sciences Corporation | $162.20 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $121.23 | 2019-2025 | |
| Astellas Pharma US INC | $110.79 | 2023-2024 | Veozah |
| Amgen INC. | $104.94 | 2019-2024 | Repatha, Otezla, Krystexxa |
| Optinose US, INC. | $95.57 | 2021-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Mcclain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.